Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ran Reshef

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2015
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumAndrew C Harris, Rachel Young, Steven Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Haematologica|August 5, 2018
Upper gastrointestinal acute graft-<i>versus</i>-host disease adds minimal prognostic value in isolation or with other graft-<i>versus</i>-host disease symptoms as currently diagnosed and treatedSarah Nikiforow, Tao Wang, Michael Hemmer, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Haematologica|June 2, 2016
Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant ResearchAleksandr Lazaryan, Tao Wang, Stephen R Spellman, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Spatiotemporal Single-Cell Analysis Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host DiseaseLingting Shi, Ajna Uzuni, Ximi K Wang, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 20, 2015
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumAndrew C Harris, Rachel Young, Steven Devine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Haematologica|August 5, 2018
Upper gastrointestinal acute graft-<i>versus</i>-host disease adds minimal prognostic value in isolation or with other graft-<i>versus</i>-host disease symptoms as currently diagnosed and treatedSarah Nikiforow, Tao Wang, Michael Hemmer, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Haematologica|June 2, 2016
Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant ResearchAleksandr Lazaryan, Tao Wang, Stephen R Spellman, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Spatiotemporal Single-Cell Analysis Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host DiseaseLingting Shi, Ajna Uzuni, Ximi K Wang, et al.
Pageof 15